ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

11103	Companies
244258	Keywords
172360	Articles
131631	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 11/04/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates

Positive Results Phase 2 Study OSE Immunotherapeutics Lusvertikimab Ulcerative Colitis Treatment
BRIEF

published on 09/10/2024 at 07:35, 2 years ago

OSE Immunotherapeutics Launches Phase 3 Study for Tedopi® in Lung Cancer

NSCLC Immunotherapy Phase 3 Trial Cancer Vaccine Global Launch
PRESS RELEASE

published on 09/10/2024 at 07:30, 2 years ago

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
OSE Immunotherapeutics launches international Phase 3 trial 'Artemia' of cancer vaccine Tedopi® in second-line NSCLC treatment, aiming for regulatory approval in Europe and North America

NSCLC Phase 3 Trial OSE Immunotherapeutics Artemia Tedopi
BRIEF

published on 07/01/2024 at 07:35, 2 years 2 months ago

OSE Immunotherapeutics Publishes Preclinical Efficacy Results for Lusvertikimab in ALL

Immunotherapy OSE Immunotherapeutics Preclinical Results Lusvertikimab Acute Lymphoblastic Leukemia
PRESS RELEASE

published on 07/01/2024 at 07:30, 2 years 2 months ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
BRIEF

published on 06/24/2024 at 07:35, 2 years 3 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 2 years 3 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 2 years 3 months ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
BRIEF

published on 06/05/2024 at 07:35, 2 years 3 months ago

OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation

Immunotherapy Clinical Test OSE Immunotherapeutics FR104/VEL-101 Kidney Transplantation
PRESS RELEASE

published on 06/05/2024 at 07:30, 2 years 3 months ago

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
OSE Immunotherapeutics and Nantes University Hospital present positive Phase 1/2 study evaluating FR104/VEL-101 immunotherapy in renal transplant at American Transplant Congress 2024

Immunotherapy Phase 1/2 Study OSE Immunotherapeutics Nantes University Hospital Renal Transplant

Accesswire

Published on 09/30/2026 at 23:30, 1 hour 27 minutes ago

Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 4 hours 22 minutes ago

Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 09/30/2026 at 15:50, 9 hours 7 minutes ago

Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 10 hours 20 minutes ago

NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 10 hours 26 minutes ago

First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week

View all ACCESSWIRE

EQS Group

Published on 09/30/2026 at 23:23, 1 hour 33 minutes ago

LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance
Published on 09/30/2026 at 22:34, 2 hours 23 minutes ago

The Change of Date of the Annual Report 2025 Publication
Published on 09/30/2026 at 22:05, 2 hours 52 minutes ago

ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model
Published on 09/30/2026 at 22:05, 2 hours 52 minutes ago

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Published on 09/30/2026 at 20:50, 4 hours 6 minutes ago

EQS-Adhoc: Avemio AG: Adverse Audit Opinion on 2025 Consolidated Financial Statements and Group Management Report – 2025 Annual Report Published

Les Echos

Published on 09/30/2026 at 18:44, 6 hours 12 minutes ago

Broadcast of the 5th edition of “On the way up”
Published on 09/30/2026 at 18:15, 6 hours 42 minutes ago

The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:00, 6 hours 57 minutes ago

Thales announces the distribution of an interim dividend
Published on 09/30/2026 at 18:00, 6 hours 57 minutes ago

Cie du Bois Sauvage : Compagnie du Bois Sauvage increases its stake in Eaglestone to support its long-term development (Inside information)
Published on 09/30/2026 at 12:00, 12 hours 57 minutes ago

Capital increase through exercise of subscription rights

View all LES ECHOS COMFI WIRE